Time to insulin in type-2 diabetes: High hurdles or Santiago way?

Acta Diabetologica

Volumn 45, Issue 2, 2008, Pages 67-74

  Rotella, Carlo Maria ^a   Pala, Laura ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Time to insulin; Type 2 diabetes therapy

Indexed keywords

ACARBOSE; CANNABINOID RECEPTOR ANTAGONIST; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; REPAGLINIDE; RIMONABANT; SAXAGLIPTIN; SIBUTRAMINE; SITAGLIPTIN; SULFONYLUREA; TETRAHYDROLIPSTATIN; VILDAGLIPTIN;

ADIPOCYTE; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES CONTROL; DIABETIC OBESITY; DIABETIC PATIENT; DRUG DOSE TITRATION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INNATE IMMUNITY; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LOW CALORY DIET; METABOLIC REGULATION; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS FUNCTION DISORDER; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; SELF MONITORING; SIDE EFFECT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION;

ALGORITHMS; ATTITUDE TO HEALTH; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; OBESITY; PREVALENCE; TIME FACTORS;

EID: 42649130662     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-008-0027-x     Document Type: Review

References (50)

1. Mittelman SD, Van Citters GW, Kirkman EL, Bergman RN (2002) Extreme insulin resistance of the central adipose depot in vivo. Diabetes 51:755-761
2. Jensen MD (2006) Is visceral fat involved in the pathogenesis of the metabolic syndrome? Human model. Obesity (Silver Spring) 14(Suppl 1):20S-24S
3. Weisberg SP et al (2003) Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808
4. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978
5. Côté M et al (2005) Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men. J Clin Endocrinol Metab 90:1434-1439
6. Lemieux I et al (2001) Contribution of interleukin-6 and tumor necrosis factor-alpha to the elevated C-reactive protein levels found in abdominally obese men. Obes Res 9:66S
7. Hotamisligil GS (2000) Molecular mechanisms of insulin resistance and the role of the adipocyte. Int J Obes Relat Metab Disord 24(Suppl 4):S23-S27
8. Miranda PJ, DeFronzo RA, Califf RM, Guyton JR (2005) Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J 149:33-45
9. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI (2000) Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 275:8456-8460
10. Gökhan SH (2006) Inflammation and metabolic disorders. Nature 444:860-867
11. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS (2006) TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest Nov;116(11):3015-3025
12. Tschop M, Thomas G (2006) Fat fuels insulin resistance through Toll-like receptors. Nat MedDec;12(12):1359-1361
13. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S (2007) Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56(4):1010-1013
14. Skurk T, Alberti-Huber C, Herder C, Hauner H (2007) Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92(3):1023-1033
15. Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE, Haffner SM (2006) The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 55(4):1114-1120
16. Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, Masotti G, Marchionni N, Mannucci E (2006) Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab Res Rev 22(6):477-482
17. Monami M, Lamanna C, Pala L, Bardini G, Cresci B, Pasqua A, Balzi D, Marchionni N, Rotella CM, Mannucci E (2008) Treatment with insulin secretagogues and cancer-related mortality in type 2 diabetic patients a retrospective cohort study. ExpClin Endocrinol Diabetes 116(3):184-189
18. Decker M, Hofflich H, Elias AN (2007) Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. Diabetes Obes Metab 21, Jul 21 [Epub ahead of print]
19. Derosa G, Fogari E, Cicero AF, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R (2007) Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 30(5):387-394
20. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24):2457-2471
21. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trias. JAMA 298(10):1180-1188
22. David MN, John BB, Mayer BD, Robert JH, Rury RH, Robert S, Bernard Z (2006) Management of Hyperglycemia in Type 2 Diabetes: a Consensus Algorithm for the Initiation and Adjustment of Therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963-1972
23. Louis M, Claude C, Gareth JD, David RO (2007) The Loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30:263-269
24. Phillips P (2005) Type 2 diabetes-failure, blame and guilt in the adoption of insulin therapy. Rev Diabet Stud 2(1):35-39
25. Mannucci E, Monami M, Pala L, Cocca C, Cresci B, Bardini G, Masotti G, Marchionni N, Rotella CM (2007) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 30(1):193-194
26. Rotella CM, Pala L, Mannucci E (2005) Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J Endocrinol Invest 28(8):746-758
27. Pala L, Mannucci E, Pezzatini A, Ciani S, Sardi J, Raimondi L, Ognibene A, Cappadona A, Vannelli BG, Rotella CM (2003) Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 310(1):28-31
28. Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I, Cremasco F, Ognibene A, Rotella CM (2005) Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 48(6):1168-1172
29. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368(9548):1696-1705
30. Gallwitz B (2005) Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass. Diabetes Technol Ther 7(4):651-657
31. Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, Pipeleers D, Ling Z, Drucker DJ (2006) GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 4(5):391-406
32. Valverde I, Villanueva-Penacarrillo ML, Malaisse WJ (2002) Pancreatic and extrapancreatic effects of GLP-1. Diabetes Metab 28(6 Pt 2):3S85-3S89
33. Vella A, Rizza RA (2004) Extrapancreatic effects of GIP and GLP-1. Horm Metab Res 36(11-12):830-836
34. Bays H, Blonde L, Rosenson R (2006) Adiposopathy: how do diet, exercise and weight loss drug therapies improve metabolic disease in overweight patients? Expert Rev Cardiovasc Ther 4(6):871-895
35. Diabetes Prevention Program Research Group (2002) Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
36. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27(1):155-161
37. DREAM (Diabetes REduction Assessment with ramipril, rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368(9541):1096-1105
38. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M STOP-NIDDM Trail Research Group (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359(9323):2072-2077
39. Mannucci E, Dicembrini I, Rotella F, Rotella CM (2007) Orlistat and sibutramine beyond weight loss. Nutr Metab Cardiovasc Dis, Oct 8 [Epub ahead of print]
40. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K (2007) Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 334(7588):299
41. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP Sibutramine/Diabetes Clinical Study Group (2000) Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2(3):175-187
42. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF; RIO-Diabetes Study Group (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368(9548):1660-1672
43. Lafontan M, Piazza PV, Girard J (2007) Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. Diabetes Metab 33(2):85-95 Epub 2007 Apr 5
44. Anna IK, Dimitri PM, Asterios K, Vasilios GA (2007) The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharm 47:642-652
45. Riddle MC (2005) Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 34:77-98
46. Chehade JM, Mooradian AD (2000) A rational approach to drug therapy of type 2 diabetes mellitus. Drugs 60:95-113
47. DeFronzo RA (1999) Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281-303
48. Edelman SV, Morello CM (2005) Strategies for insulin therapy in type 2 diabetes. South Med J 98:363-371
49. Pala L, Mannucci E, Dicembrini I, Rotella CM (2007) A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients. Diabetes Res Clin Pract Apr 17
50. Blonde L, Klein EJ, Han J et al (2006) Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. DOM 8:436-447